The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis

April 13, 2026 updated by: Zhongnan Hospital
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study investigates the pathogenesis of PACG by conducting multi-omics analyses of aqueous humor, blood and anterior lens capsule samples from PACG patients with and without concomitant zonular abnormalities, aiming to elucidate the etiology of zonular abnormalities and uncover novel mechanisms underlying their involvement in the pathogenesis of glaucoma.

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430000
        • Recruiting
        • Zhongnan Hospital of Wuhan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.

Description

Inclusion Criteria:

  • Clinically diagnosed with primary angle-closure glaucoma (PACG)
  • Aged ≥ 50 years, no gender restriction
  • Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
  • Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
  • Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery

Exclusion Criteria:

  • Secondary glaucoma
  • History of previous intraocular surgery
  • Systemic diseases that can cause abnormal ocular zonules
  • Other severe ocular diseases
  • Long-term use of medications affecting connective tissue metabolism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Case Group A
PACG patients with zonular laxity
Other: No Additional Experimental Intervention
No Additional Experimental Intervention
Case Group B
PACG patients without zonular laxity
Other: No Additional Experimental Intervention
No Additional Experimental Intervention
Control Group
cataract patients without a history or signs of glaucoma
Other: No Additional Experimental Intervention
No Additional Experimental Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of differentially expressed molecules in PACG patients with zonular laxity
Time Frame: 2 years
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhongnan Hospital

Investigators

  • Study Director: Wen Zeng, doctor, Zhongnan Hospital
  • Study Director: Nan Zhang, doctor, Zhongnan Hospital
  • Principal Investigator: Xuetian Yu, student, The Second Clinical College of Wuhan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2025

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

March 20, 2026

First Submitted That Met QC Criteria

April 13, 2026

First Posted (Actual)

April 20, 2026

Study Record Updates

Last Update Posted (Actual)

April 20, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20260122xrd

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Angle-Closure Glaucoma

Clinical Trials on No Additional Experimental Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe